Close

Anti-TERT TCR-NK Cells (XS-0623-ZP101)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The genetically modified anti-TERT TCR-NK cell is designed to target to the specific epitope-HLA complex. The TCR-NK is expected to show antigen-specific cytotoxicity against TERT antigen via the introduced TCR were successfully produced.

  Add to Cart

Specifications

  • Cell Type
  • TCR-NK
  • Host Cell Type
  • Primary NK cells

TCR Design

  • Target
  • TERT
  • Common Name
  • TERT
  • Target Species
  • Human
  • TCR-Host Animal
  • Human
  • Vector Name
  • pCDTCR1
  • Vector length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
Sub CAT. HLA TCR Clone Epitope  
XS-0623-ZP101-SUB1 HLA-A2 ILA1β2 ILAKFLHWL
XS-0623-ZP101-SUB2 HLA-A02 CB2A20 RLVDDFLLV

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-TERT TCR-NK Cells (XS-0623-ZP101). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.